Prognostic value of cytokeratin-positive bone marrow cells of gastric cancer patients

Annals of Surgical Oncology

Volumn 14, Issue 2, 2007, Pages 373-380

  Gretschel, Stephan ^a   Schick, Christian ^a   Schneider, Ulrike ^a   Estevez Schwarz, Lope ^a   Bembenek, Andreas ^a   Schlag, Peter M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Bone marrow; Epithelial cells; Gastric cancer

Indexed keywords

CYTOKERATIN;

ADULT; ARTICLE; ASPIRATION CYTOLOGY; BONE MARROW CELL; CANCER SURVIVAL; COURSE EVALUATION; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; ILIAC CREST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREOPERATIVE EVALUATION; PROGNOSIS; PROSPECTIVE STUDY; RECURRENCE RISK; STOMACH CANCER; SURGICAL PATIENT; SURVIVAL RATE; SURVIVAL TIME;

AGED; BONE MARROW CELLS; CELL COUNT; DISEASE-FREE SURVIVAL; EPITHELIAL CELLS; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-18; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSPECTIVE STUDIES; STOMACH NEOPLASMS;

EID: 33846584549     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9039-3     Document Type: Article

References (51)

1. Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 1987; 11:418-25.
2. Roder JD, Bottcher K, Siewert JR, Busch R, Hermanek P, Meyer HJ. Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 1992. Cancer 1993; 72:2089-97.
3. D'Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004; 240:808-16.
4. Sakar B, Karagol H, Gumus M, et al. Timing of death from tumor recurrence after curative gastrectomy for gastric cancer. Am J Clin Oncol 2004; 27:205-9.
5. Tajima Y, Yamazaki K, Nishino N, et al. Gastric and intestinal phenotypic marker expression in gastric carcinomas and recurrence pattern after surgery - immunohistochemical analysis of 213 lesions. Br J Cancer 2004; 91:1342-8.
6. Harrison LE, Choe JK, Goldstein M, Meridian A, Kim SH, Clarke K. Prognostic significance of immunohistochemical micrometastases in node negative gastric cancer patients. J Surg Oncol 2000; 73:153-7.
7. Maehara Y, Oshiro T, Endo K, et al. Clinical significance of occult micrometastasis lymph nodes from patients with early gastric cancer who died of recurrence. Surgery 1996; 119:397-402.
8. Ishida K, Katsuyama T, Sugiyama A, Kawasaki S. Immunohistochemical evaluation of lymph node micrometastases from gastric carcinomas. Cancer 1997; 79:1069-76.
9. Cai J, Ikeguchi M, Tsujitani S, Maeta M, Kaibara N. Micrometastasis in lymph nodes of mucosal gastric cancer. Gastric Cancer 2000; 3:91-6.
10. Fukagawa T, Sasako M, Mann GB, et al. Immunohistochemically detected micrometastases of the lymph nodes in patients with gastric carcinoma. Cancer 2001; 92:753-60.
11. Schott A, Vogel I, Krueger U, et al. Isolated tumor cells are frequently detectable in the peritoneal cavity of gastric and colorectal cancer patients and serve as a new prognostic marker. Ann Surg 1998; 227:372-9.
12. Vogel P, Ruschoff J, Kummel S, et al. Prognostic value of microscopic peritoneal dissemination: comparison between colon and gastric cancer. Dis Colon Rectum 2000; 43:92-100.
13. Nakanishi H, Kodera Y, Yamamura Y, et al. Rapid quantitative detection of carcinoembryonic antigen-expressing free tumor cells in the peritoneal cavity of gastric-cancer patients with real-time RT-PCR on the lightcycler. Int J Cancer 2000; 89:411-7.
14. Yonemura Y, Fujimura T, Ninomiya I, et al. Prediction of peritoneal micrometastasis by peritoneal lavaged cytology and reverse transcriptase- polymerase chain reaction for matrix metalloproteinase-7 mRNA. Clin Cancer Res 2001; 7:1647-53.
15. Thorban S, Rosenberg R, Busch R, Roder RJ. Epithelial cells in bone marrow of oesophageal cancer patients: a significant prognostic factor in multivariate analysis. Br J Cancer 2000; 83:35-9.
16. Schlimok G, Funke I, Pantel K, et al. Micrometastatic tumour cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance. Eur J Cancer 1991; 27:1461-5.
17. Juhl H, Stritzel M, Wroblewski A, et al. Immunocytological detection of micrometastatic cells: comparative evaluation of findings in the peritoneal cavity and the bone marrow of gastric, colorectal and pancreatic cancer patients. Int J Cancer 1994; 57:330-5.
18. Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmuller G. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 1992; 340:685-9.
19. Neumaier M, Gerhard M, Wagener C. Diagnosis of micrometastases by the amplification of tissue-specific genes. Gene 1995; 159:43-7.
20. Sloane JP, Ormerod MG, Neville AM. Potential pathological application of immunocytochemical methods to the detection of micrometastases. Cancer Res 1980; 40:3079-82.
21. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997; 80:1803-4.
22. Wittekind C, Compton CC, Greene FL, Sobin LH. TNM residual tumor classification revisited. Cancer 2002; 94:2511-6.
23. Hermanek P, Hutter RV, Sobin LH, Wittekind C. International Union Against Cancer. Classification of isolated tumor cells and micrometastasis. Cancer 1999; 86:2668-73.
24. Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984; 32:219-29.
25. Gerhartz HH, Schmetzer H. Detection of minimal residual disease in acute myeloid leukemia. Leukemia 1990; 4:508-16.
26. Moll R, Franke WW. Intermediate filaments and their interaction with membranes. The desmosome-cytokeratin filament complex and epithelial differentiation. Pathol Res Pract 1982; 175:146-61.
27. Soligo D, Lambertenghi-Deliliers G, Berti E, Polli N, Polli EE. Immunohistochemical evaluation of bone marrow involvement in hairy cell leukemia during interferon therapy. Blut 1987; 55:121-6.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53:457-81.
29. Cox CP. On estimating relative potency from quadratic log-dose response relationships. Biometrics 1972; 28:875-81.
30. Broll R, Lembcke K, Stock C, et al. Tumor cell dissemination in bone marrow and peritoneal cavity. An immunocytochemical study of patients with stomach or colorectal carcinoma (in German). Langenbecks Arch Chir 1996; 381:51-8.
31. Kakeji Y, Maehara Y, Shibahara K, et al. Clinical significance of micrometastasis in bone marrow of patients with gastric cancer and its relation to angiogenesis. Gastric Cancer 1999; 2:46-51.
32. Jauch KW, Heiss MM, Gruetzner U, et al. Prognostic significance of bone marrow micrometastases in patients with gastric cancer. J Clin Oncol 1996; 14:1810-7.
33. Macadam R, Sarela A, Wilson J, MacLennan K, Guillou P. Bone marrow micrometastases predict early post-operative recurrence following surgical resection of oesophageal and gastric carcinoma. Eur J Surg Oncol 2003; 29:450-4.
34. Maehara Y, Hasuda S, Abe T, et al. Tumor angiogenesis and micrometastasis in bone marrow of patients with early gastric cancer. Clin Cancer Res 1998; 4:2129-34.
35. O'Sullivan GC, Collins JK, O-Brien F, et al. Micrometastases in bone marrow of patients undergoing "curative" surgery for gastrointestinal cancer. Gastroenterology 1995; 109:1535-40.
36. Allgayer H, Heiss MM, Riesenberg R, Babic R, Jauch KW, Schildberg FW. Immunocytochemical phenotyping of disseminated tumor cells in bone marrow by uPA receptor and CK18: investigation of sensitivity and specificity of an immunogold/alkaline phosphatase double staining protocol. J Histochem Cytochem 1997; 45:203-12.
37. Funke I, Fries S, Rolle M, et al. Comparative analyses of bone marrow micrometastases in breast and gastric cancer. Int J Cancer 1996; 65:755-61.
38. Heiss MM, Allgayer H, Gruetzner KU, Babic R, Jauch KW, Schildberg FW. Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer. Ann Surg 1997; 226:736-44.
39. Heiss MM, Simon EH, Beyer BC, et al. Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow. J Clin Oncol 2002; 20:2005-16.
40. Maehara Y, Yamamoto M, Oda S, et al. Cytokeratin-positive cells in bone marrow for identifying distant micrometastasis of gastric cancer. Br J Cancer 1996; 73:83-7.
41. Ryan P, McCarthy S, Kelly J, et al. Prevalence of bone marrow micrometastases in esophagogastric cancer patients with and without neoadjuvant chemoradiotherapy. J Surg Res 2004; 117:121-6.
42. O'Sullivan GC, Sheehan D, Clarke A, et al. Micrometastases in esophagogastric cancer: high detection rate in resected rib segments. Gastroenterology 1999; 116:543-8.
43. Bonavina L, Soligo D, Quirici N, et al. Bone marrow-disseminated tumor cells in patients with carcinoma of the esophagus or cardia. Surgery 2001; 129:15-22.
44. de Manzoni G, Pelosi G, Pavanel F, et al. The presence of bone marrow cytokeratin-immunoreactive cells does not predict outcome in gastric cancer patients. Br J Cancer 2002; 86:1047-51.
45. Matsunami K, Nakamura T, Oguma H, Kitamura Y, Takasaki K. Detection of bone marrow micrometastasis in gastric cancer patients by immunomagnetic separation. Ann Surg Oncol 2003; 10:171-5.
46. Jonas S, Weinrich M, Tullius SG, et al. Microscopic tumor cell dissemination in gastric cancer. Surg Today 2004; 34:101-6.
47. Pantel K, Schlimok G, Kutter D, et al. Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res 1991; 51:4712-5.
48. Andratschke M, Pauli C, Stein M, Chaubal S, Wollenberg B. MHC-class I antigen expression on micrometastases in bone marrow of patients with head and neck squamous cell cancer. Anticancer Res 2003; 23:1467-71.
49. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994; 1198:165-84.
50. Maxwell-Armstrong CA, Durrant LG, Scholefield JH. Immunotherapy for colorectal cancer. Am J Surg 1999; 177:344-8.
51. Vermorken JB, Claessen AM, van Tinteren H, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999; 353:345-50.